Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Role of Nanomedicine for Targeted Drug Delivery in Livestock: Future Prospective

Author(s): Neeti Hooda, Aarti Ahlawat, Puja Kumari, Md. Sabir Alam and Jamilur R. Ansari*

Volume 13, Issue 3, 2025

Published on: 28 November, 2023

Page: [479 - 496] Pages: 18

DOI: 10.2174/0122117385267911231109184511

Price: $65

Abstract

Nanotechnology has advanced significantly in recent years and is currently used in a wide range of sectors. Only a handful of the many diverse issues covered by nanotechnology include nanoscale gadgets, nanomaterials, nanoparticles, and nanomedicines. Its performance in treating a range of grave conditions, such as cancer, early detection of infections, analysis, bio-imaging, and bio sensing, suggests that it is highly advanced. Nanoscale materials have been employed for medicine delivery, pharmaceutics, and a range of diagnostic techniques due to their various biochemical and physical features. The use of nanoparticles that are based on nanotechnology can significantly improve the drug delivery mechanism. It is believed that nanoparticles capacity to improve the stability and solubility of drugs and shield them from impulsive inactivation during drug transfer makes it possible for them to capture, encapsulate, or bond with the molecules. The use of nanomedicine or nanoparticle-based tactics to combat viruses has emerged as a potentially life-saving tactic. These approaches have the power to protect both humans and animals against viruses. In order to inactivate a virus, nanoparticles have the unique capacity to connect with the virus epitope. Many nanocarriers have the potential to replace current drug delivery methods with focused drug delivery. Small dosages, low toxicity, and targeted flow of drug release at the infected location are all characteristics of nanocarriers or nanomedicine. Due to their distinct physicochemical and biological features, nanomaterial- based drug delivery systems (NBDDS) are frequently employed to enhance the safety and therapeutic efficacy of encapsulated pharmaceuticals. The program’s objective can be supported by the applications that have so far been developed. This idea is therefore essential and sophisticated for the development of civilization. Our research will therefore concentrate on how human use of nanomedicines has changed through time in many domains.

Keywords: Clinical efficacy, drug delivery, magnetic nanoparticles, nanomedicine, quantum dots, livestock.

« Previous Next »
Graphical Abstract

[1]
Sadikot RT, Rubinstein I. Long-acting, multi-targeted nanomedicine: addressing unmet medical need in acute lung injury. J Biomed Nanotechnol 2009; 5(6): 614-9.
[http://dx.doi.org/10.1166/jbn.2009.1078] [PMID: 20201223]
[2]
Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine 2005; 1(3): 193-212.
[http://dx.doi.org/10.1016/j.nano.2005.06.004] [PMID: 17292079]
[3]
Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006; 24(10): 1211-7.
[http://dx.doi.org/10.1038/nbt1006-1211] [PMID: 17033654]
[4]
Singhal S, Gupta M, Alam MS, Javed MN, Ansari JR. Carbon Allotropes-Based Nanodevices: Graphene in Biomedical Applications InNanotechnology. CRC Press 2022; pp. 241-69.
[http://dx.doi.org/10.1201/9781003220350-14]
[5]
Bhandari M, Raj S, Manchanda R, Alam MS. Review on natural bioactive products as radioprotective therapeutics: Present and past perspective. Curr Pharm Biotechnol 2022; 23(14): 1721-38.
[http://dx.doi.org/10.2174/1389201023666220110104645] [PMID: 35016594]
[6]
Kumar R, Dhamija G, Ansari JR, Javed MN, Alam MS. C-Dot nanoparticulated devices for biomedical applications. In: Nanotechnology. CRC Press 2022; pp. 271-99.
[7]
Bharti C, Alam MS, Javed MN, Khalid M, Saifullah FA, Manchanda R. Silica based nanomaterial for drug delivery. Nanomaterials. Evolution and Advance Towards Therapeutic Drug Delivery 2021; (Part 2): 57-89.
[8]
Pandit J, Alam MS, Javed MN, Waziri A, Imam SS. Emerging roles of carbon nanohorns as sustainable nanomaterials in sensor, catalyst, and biomedical applications. In: Handbook of Green and Sustainable Nanotechnology: Fundamentals, Developments and Applications. Cham: Springer International Publishing 2023; pp. 1-27.
[9]
Mall SK, Yadav T, Waziri A, Alam MS. Treatment opportunities with Fernandoa adenophylla and recent novel approaches for natural medicinal phytochemicals as a drug delivery system. Exploration of Medicine 2022; 3(6): 516-39.
[http://dx.doi.org/10.37349/emed.2022.00111]
[10]
Bhandari M, Kaur DP, Raj S, Yadav T, Abourehab MA, Alam MS. Electrically conducting smart biodegradable polymers and their applications. In: Handbook of Biodegradable Materials. Cham: Springer International Publishing 2023; pp. 391-413.
[http://dx.doi.org/10.1007/978-3-031-09710-2_64]
[11]
Naseh MF, Ansari JR, Alam MS, Javed MN. Sustainable nanotorus for biosensing and therapeutical applications. In: Handbook of Green and Sustainable Nanotechnology: Fundamentals, Developments and Applications. Cham: Springer International Publishing 2022; pp. 1-21.
[http://dx.doi.org/10.1007/978-3-030-69023-6_47-1]
[12]
Sunilbhai CA, Alam MS, Sadasivuni KK, Ansari JR. SPR assisted diabetes detection. In: Advanced Bioscience and Biosystems for Detection and Management of Diabetes. Cham: Springer International Publishing 2022; pp. 91-131.
[http://dx.doi.org/10.1007/978-3-030-99728-1_6]
[13]
Singhal S, Gupta M, Alam MS, Javed MN, Ansari JR. Carbon allotropes-based nanodevices: Graphene in biomedical applications. In: Nanotechnology. CRC Press 2022; pp. 241-69.
[http://dx.doi.org/10.1201/9781003220350-14]
[14]
Rampado R, Peer D. Design of experiments in the optimization of nanoparticle-based drug delivery systems. J Control Release 2023; 358: 398-419.
[http://dx.doi.org/10.1016/j.jconrel.2023.05.001] [PMID: 37164240]
[15]
Ramazanli VN. Effect of ph and temperature on the synthesis of silver nano particles extracted from olive leaf. https://www.ablesci.com/assist/detail?id=X1zbZA
[16]
Nasibova A. Generation Of Nanoparticles In Biological Systems And Their Application Prospects, Advances in Biology &. Earth Sci 8: 2023. n.d.
[17]
Ahmadov IS, Bandaliyeva AA, Nasibova AN, Hasanova FV, Khalilov RI. The synthesis of the silver nanodrugs in the medicinal plant baikal skullcap (scutellaria baicalensis georgi) and their antioxidant, antibacterial activity. In: Advances in Biology & Earth Sciences. 2020.
[18]
Ouyang J, Zhang Z, Deng B, et al. Oral drug delivery platforms for biomedical applications. Mater Today 2023; 62: 296-326.
[http://dx.doi.org/10.1016/j.mattod.2023.01.002]
[19]
Cooke JP, Atkins J. Nanotherapeutic solutions for cardiovascular disease. Methodist DeBakey Cardiovasc J 2016; 12(3): 132-3.
[http://dx.doi.org/10.14797/mdcj-12-3-132] [PMID: 27826365]
[20]
Zhou X, Hao Y, Yuan L, et al. Nano-formulations for transdermal drug delivery: A review. Chin Chem Lett 2018; 29(12): 1713-24.
[http://dx.doi.org/10.1016/j.cclet.2018.10.037]
[21]
Matoba T, Koga J, Nakano K, Egashira K, Tsutsui H. Nanoparticle-mediated drug delivery system for atherosclerotic cardiovascular disease. J Cardiol 2017; 70(3): 206-11.
[http://dx.doi.org/10.1016/j.jjcc.2017.03.005] [PMID: 28416142]
[22]
Tiance AN, Zhang L Versatile flexible azolate-based metal-organic frameworks possessing different bridging ligands. J Mater Res 2016; 4(2)
[23]
Landesman-Milo D, Goldsmith M, Leviatan Ben-Arye S, et al. Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Lett 2013; 334(2): 221-7.
[http://dx.doi.org/10.1016/j.canlet.2012.08.024] [PMID: 22935680]
[24]
Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev 2016; 68(3): 701-87.
[http://dx.doi.org/10.1124/pr.115.012070] [PMID: 27363439]
[25]
Chandrasekaran S, King M. Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy. Int J Mol Sci 2014; 15(11): 20209-39.
[http://dx.doi.org/10.3390/ijms151120209] [PMID: 25380524]
[26]
Chapoy-Villanueva H, Martinez-Carlin I, Lopez-Berestein G, Chavez-Reyes A. Therapeutic silencing of HPV 16 E7 by systemic administration of siRNA-neutral DOPC nanoliposome in a murine cervical cancer model with obesity. J BUON 2015; 20(6): 1471-9.
[PMID: 26854443]
[27]
Fan Y, Chen C, Huang Y, Zhang F, Lin G. Study of the pH-sensitive mechanism of tumor-targeting liposomes. Colloids Surf B Biointerfaces 2017; 151: 19-25.
[http://dx.doi.org/10.1016/j.colsurfb.2016.11.042] [PMID: 27940165]
[28]
Shi C, He Y, Ding M, Wang Y, Zhong J. Nanoimaging of food proteins by atomic force microscopy. Part I: Components, imaging modes, observation ways, and research types. Trends Food Sci Technol 2019; 87: 3-13.
[http://dx.doi.org/10.1016/j.tifs.2018.11.028]
[29]
Shi C, He Y, Ding M, Wang Y, Zhong J. Nanoimaging of food proteins by atomic force microscopy. Part II: Application for food proteins from different sources. Trends Food Sci Technol 2019; 87: 14-25.
[http://dx.doi.org/10.1016/j.tifs.2018.11.027]
[30]
Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release 2012; 161(2): 505-22.
[http://dx.doi.org/10.1016/j.jconrel.2012.01.043] [PMID: 22353619]
[31]
Wei D, Qiao R, Dao J, et al. Soybean lecithin‐mediated nanoporous PLGA microspheres with highly entrapped and controlled released BMP‐2 as a stem cell platform. Small 2018; 14(22): 1800063.
[http://dx.doi.org/10.1002/smll.201800063] [PMID: 29682876]
[32]
Zhao L, Ding J, Xiao C, et al. Glucose-sensitive polypeptide micelles for self-regulated insulin release at physiological pH. J Mater Chem 2012; 22(24): 12319-28.
[http://dx.doi.org/10.1039/c2jm31040f]
[33]
Afsharzadeh M, Hashemi M, Mokhtarzadeh A, Abnous K, Ramezani M. Recent advances in co-delivery systems based on polymeric nanoparticle for cancer treatment. Artif Cells Nanomed Biotechnol 2018; 46(6): 1095-110.
[http://dx.doi.org/10.1080/21691401.2017.1376675] [PMID: 28954547]
[34]
Wang W, Ding J, Xiao C, et al. Synthesis of amphiphilic alternating polyesters with oligo(ethylene glycol) side chains and potential use for sustained release drug delivery. Biomacromolecules 2011; 12(7): 2466-74.
[http://dx.doi.org/10.1021/bm200668n] [PMID: 21649444]
[35]
Yang C, Gao S, Dagnæs-Hansen F, Jakobsen M, Kjems J. Impact of PEG chain length on the physical properties and bioactivity of PEGylated chitosan/siRNA nanoparticles in vitro and in vivo. ACS Appl Mater Interfaces 2017; 9(14): 12203-16.
[http://dx.doi.org/10.1021/acsami.6b16556] [PMID: 28332829]
[36]
Sun P, Huang W, Kang L, et al. siRNA-loaded poly(histidine-arginine)6-modified chitosan nanoparticle with enhanced cell-penetrating and endosomal escape capacities for suppressing breast tumor metastasis. Int J Nanomedicine 2017; 12: 3221-34.
[http://dx.doi.org/10.2147/IJN.S129436] [PMID: 28458542]
[37]
Newkome GR, Yao Z, Baker GR, Gupta VK. Micelles. Part 1. Cascade molecules: a new approach to micelles. A [27]-arborol. J Org Chem 1985; 50(11): 2003-4.
[http://dx.doi.org/10.1021/jo00211a052]
[38]
Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012; 33(29): 7138-50.
[http://dx.doi.org/10.1016/j.biomaterials.2012.06.068] [PMID: 22796160]
[39]
Baeza A, Ruiz-Molina D, Vallet-Regí M. Recent advances in porous nanoparticles for drug delivery in antitumoral applications: inorganic nanoparticles and nanoscale metal-organic frameworks. Expert Opin Drug Deliv 2017; 14(6): 783-96.
[http://dx.doi.org/10.1080/17425247.2016.1229298] [PMID: 27575454]
[40]
Alam MS, Garg A, Pottoo FH, et al. Gum ghatti mediated, one pot green synthesis of optimized gold nanoparticles: Investigation of process-variables impact using Box-Behnken based statistical design. Int J Biol Macromol 2017; 104(Pt A): 758-67.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.05.129] [PMID: 28601649]
[41]
Alam MS, Javed MN, Pottoo FH, et al. QbD approached comparison of reaction mechanism in microwave synthesized gold nanoparticles and their superior catalytic role against hazardous nirto‐dye. Appl Organomet Chem 2019; 33(9): e5071.
[http://dx.doi.org/10.1002/aoc.5071]
[42]
Javed MN, Pottoo FH, Alam MS. Metallic nanoparticle alone and/or in combination as novel agent for the treatment of uncontrolled electric conductance related disorders and/or seizure, epilepsy & convulsions. WO Patent 2017060916A1, 2016.
[43]
Pandit J, Alam MS, Ansari JR, et al. Multifaced applications of nanoparticles in biological science. In: Nanomaterials in the Battle Against Pathogens and Disease Vectors. CRC Press 2022; pp. 17-50.
[http://dx.doi.org/10.1201/9781003126256-2]
[44]
Alam MS, Naseh MF, Ansari JR, et al. 3 Synthesis Approaches. In: Nanomaterials in the Battle Against Pathogens and Disease Vectors. 2022; p. 51.
[45]
Di Pietro P, Strano G, Zuccarello L, Satriano C. Gold and silver nanoparticles for applications in theranostics. Curr Top Med Chem 2016; 16(27): 3069-102.
[http://dx.doi.org/10.2174/1568026616666160715163346] [PMID: 27426869]
[46]
Liang JJ, Zhou YY, Wu J, Ding Y. Gold nanoparticle-based drug delivery platform for antineoplastic chemotherapy. Curr Drug Metab 2014; 15(6): 620-31.
[http://dx.doi.org/10.2174/1389200215666140605131427] [PMID: 24909418]
[47]
Khafaji M, Zamani M, Golizadeh M, Bavi O. Inorganic nanomaterials for chemo/photothermal therapy: a promising horizon on effective cancer treatment. Biophys Rev 2019; 11(3): 335-52.
[http://dx.doi.org/10.1007/s12551-019-00532-3] [PMID: 31102198]
[48]
Hauser AK, Mitov MI, Daley EF, McGarry RC, Anderson KW, Hilt JZ. Targeted iron oxide nanoparticles for the enhancement of radiation therapy. Biomaterials 2016; 105: 127-35.
[http://dx.doi.org/10.1016/j.biomaterials.2016.07.032] [PMID: 27521615]
[49]
Jayagopal A, Su YR, Blakemore JL, Linton MF, Fazio S, Haselton FR. Quantum dot mediated imaging of atherosclerosis. Nanotechnology 2009; 20(16): 165102.
[http://dx.doi.org/10.1088/0957-4484/20/16/165102] [PMID: 19420562]
[50]
Wei H, Bruns OT, Kaul MG, et al. Exceedingly small iron oxide nanoparticles as positive MRI contrast agents. Proc Natl Acad Sci USA 2017; 114(9): 2325-30.
[http://dx.doi.org/10.1073/pnas.1620145114] [PMID: 28193901]
[51]
Su X, Chan C, Shi J, et al. A graphene quantum dot@Fe 3 O 4 @SiO 2 based nanoprobe for drug delivery sensing and dual-modal fluorescence and MRI imaging in cancer cells. Biosens Bioelectron 2017; 92: 489-95.
[http://dx.doi.org/10.1016/j.bios.2016.10.076] [PMID: 27839733]
[52]
Wang W, Sun X, Zhang H, et al. Controlled release hydrogen sulfide delivery system based on mesoporous silica nanoparticles protects graft endothelium from ischemia–reperfusion injury. Int J Nanomedicine 2016; 11: 3255-63.
[http://dx.doi.org/10.2147/IJN.S104604] [PMID: 27486324]
[53]
Perioli L, Pagano C, Ceccarini MR. Current highlights about the safety of inorganic nanomaterials in healthcare. Curr Med Chem 2019; 26(12): 2147-65.
[http://dx.doi.org/10.2174/0929867325666180723121804] [PMID: 30033865]
[54]
Mishra S, Sharma S, Javed MN, et al. Bioinspired nanocomposites: applications in disease diagnosis and treatment. Pharm Nanotechnol 2019; 7(3): 206-19.
[http://dx.doi.org/10.2174/2211738507666190425121509] [PMID: 31030662]
[55]
Javed MN, Alam MS, Waziri A, et al. QbD applications for the development of nanopharmaceutical products. In: Pharmaceutical quality by design. Academic Press 2019; pp. 229-53.
[http://dx.doi.org/10.1016/B978-0-12-815799-2.00013-7]
[56]
Bertrand N, Leroux JC. The journey of a drug-carrier in the body: An anatomo-physiological perspective. J Control Release 2012; 161(2): 152-63.
[http://dx.doi.org/10.1016/j.jconrel.2011.09.098] [PMID: 22001607]
[57]
Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives. J Control Release 2016; 240: 489-503.
[http://dx.doi.org/10.1016/j.jconrel.2016.06.012] [PMID: 27287891]
[58]
Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics 2019; 20(2): 273-86.
[http://dx.doi.org/10.1093/biostatistics/kxx069] [PMID: 29394327]
[59]
Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009; 3(1): 16-20.
[http://dx.doi.org/10.1021/nn900002m] [PMID: 19206243]
[60]
Xu X, Ho W, Zhang X, Bertrand N, Farokhzad O. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med 2015; 21(4): 223-32.
[http://dx.doi.org/10.1016/j.molmed.2015.01.001] [PMID: 25656384]
[61]
Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine 2015; 10: 975-99.
[http://dx.doi.org/10.2147/IJN.S68861] [PMID: 25678787]
[62]
Liang R, Wei M, Evans DG, Duan X. Inorganic nanomaterials for bioimaging, targeted drug delivery and therapeutics. Chem Commun (Camb) 2014; 50(91): 14071-81.
[http://dx.doi.org/10.1039/C4CC03118K] [PMID: 24955443]
[63]
Englert C, Brendel JC, Majdanski TC, et al. Pharmapolymers in the 21st century: Synthetic polymers in drug delivery applications. Prog Polym Sci 2018; 87: 107-64.
[http://dx.doi.org/10.1016/j.progpolymsci.2018.07.005]
[64]
Taresco V, Alexander C, Singh N, Pearce AK. Stimuli‐responsive prodrug chemistries for drug delivery. Adv Ther 2018; 1(4): 1800030.
[http://dx.doi.org/10.1002/adtp.201800030]
[65]
Rampaka R, Ommi K, Chella N. Role of solid lipid nanoparticles as drug delivery vehicles on the pharmacokinetic variability of Erlotinib HCl. J Drug Deliv Sci Technol 2021; 66: 102886.
[http://dx.doi.org/10.1016/j.jddst.2021.102886]
[66]
La-Beck NM, Liu X, Wood LM. Harnessing liposome interactions with the immune system for the next breakthrough in cancer drug delivery. Front Pharmacol 2019; 10: 220.
[http://dx.doi.org/10.3389/fphar.2019.00220] [PMID: 30914953]
[67]
Indoria S, Singh V, Hsieh MF. Recent advances in theranostic polymeric nanoparticles for cancer treatment: A review. Int J Pharm 2020; 582: 119314.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119314] [PMID: 32283197]
[68]
Thapa RK, Ku SK, Choi HG, Yong CS, Byeon JH, Kim JO. Vibrating droplet generation to assemble zwitterion-coated gold-graphene oxide stealth nanovesicles for effective pancreatic cancer chemo-phototherapy. Nanoscale 2018; 10(4): 1742-9.
[http://dx.doi.org/10.1039/C7NR07603G] [PMID: 29308494]
[69]
Rozalen M, Sánchez-Polo M, Fernández-Perales M, Widmann TJ, Rivera-Utrilla J. Synthesis of controlled-size silver nanoparticles for the administration of methotrexate drug and its activity in colon and lung cancer cells. RSC Adv 2020; 10(18): 10646-60.
[http://dx.doi.org/10.1039/C9RA08657A] [PMID: 35492913]
[70]
Halevas EG, Pantazaki AA. Copper nanoparticles as therapeutic anticancer agents. Nanomed Nanotechnol J 2018; 2(1): 119-39.
[71]
Dutta SD, Ganguly K, Bandi R, Alle M. A new era of cancer treatment: Carbon nanotubes as drug delivery tools. In: Smart Nanomaterials in Biomedical Applications. Cham: Springer International Publishing 2022; pp. 155-71.
[72]
Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater 2016; 1(5): 16014.
[http://dx.doi.org/10.1038/natrevmats.2016.14]
[73]
Hrubý M, Filippov SK, Štěpánek P. Smart polymers in drug delivery systems on crossroads: Which way deserves following? Eur Polym J 2015; 65: 82-97.
[http://dx.doi.org/10.1016/j.eurpolymj.2015.01.016]
[74]
Javed MN, Dahiya ES, Ibrahim AM, Alam MS, Khan FA, Pottoo FH. Recent advancement in clinical application of nanotechnological approached targeted delivery of herbal drugs. In: Beg S, Barkat M, Ahmad F, Eds. Nanophytomedicine. Singapore: Springer 2020.
[http://dx.doi.org/10.1007/978-981-15-4909-0_9]
[75]
Javed MN, Pottoo FH, Shamim A, Hasnain MS, Alam MS. Design of experiments for the development of nanoparticles, nanomaterials, and nanocomposites. In: Design of Experiments for Pharmaceutical Product Development: Volume II: Applications and Practical Case studies. 2021; pp. 151-69.
[http://dx.doi.org/10.1007/978-981-33-4351-1_9]
[76]
Kopeček J, Yang J. Hydrogels as smart biomaterials. Polym Int 2007; 56(9): 1078-98.
[http://dx.doi.org/10.1002/pi.2253]
[77]
Lee BK, Yun YH, Park K. Smart nanoparticles for drug delivery: Boundaries and opportunities. Chem Eng Sci 2015; 125: 158-64.
[http://dx.doi.org/10.1016/j.ces.2014.06.042] [PMID: 25684780]
[78]
Bamrungsap S, Zhao Z, Chen T, et al. Nanotechnology in therapeutics: A focus on nanoparticles as a drug delivery system. Nanomedicine 2012; 7(8): 1253-71.
[http://dx.doi.org/10.2217/nnm.12.87] [PMID: 22931450]
[79]
Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev 2013; 65(1): 36-48.
[http://dx.doi.org/10.1016/j.addr.2012.09.037] [PMID: 23036225]
[80]
Couvreur P. Nanoparticles in drug delivery: Past, present and future. Adv Drug Deliv Rev 2013; 65(1): 21-3.
[http://dx.doi.org/10.1016/j.addr.2012.04.010] [PMID: 22580334]
[81]
Alvarez-Lorenzo C, Concheiro A. Smart drug delivery systems: From fundamentals to the clinic. Chem Commun 2014; 50(58): 7743-65.
[http://dx.doi.org/10.1039/C4CC01429D] [PMID: 24805962]
[82]
Crommelin DJA, Florence AT. Towards more effective advanced drug delivery systems1. Int J Pharm 2013; 454(1): 496-511.
[http://dx.doi.org/10.1016/j.ijpharm.2013.02.020] [PMID: 23415662]
[83]
Holzapfel BM, Reichert JC, Schantz JT, et al. How smart do biomaterials need to be? A translational science and clinical point of view. Adv Drug Deliv Rev 2013; 65(4): 581-603.
[http://dx.doi.org/10.1016/j.addr.2012.07.009] [PMID: 22820527]
[84]
Grund S, Bauer M, Fischer D. Polymers in drug delivery—state of the art and future trends. Adv Eng Mater 2011; 13(3): B61-87.
[http://dx.doi.org/10.1002/adem.201080088]
[85]
Annabi N, Tamayol A, Uquillas JA, et al. 25th anniversary article: Rational design and applications of hydrogels in regenerative medicine. Adv Mater 2014; 26(1): 85-124.
[http://dx.doi.org/10.1002/adma.201303233] [PMID: 24741694]
[86]
Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2012; 7: 49-60.
[PMID: 22275822]
[87]
Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010; 75(1): 1-18.
[http://dx.doi.org/10.1016/j.colsurfb.2009.09.001] [PMID: 19782542]
[88]
Rossi F, Ferrari R, Castiglione F, Mele A, Perale G, Moscatelli D. Polymer hydrogel functionalized with biodegradable nanoparticles as composite system for controlled drug delivery. Nanotechnology 2015; 26(1): 015602.
[http://dx.doi.org/10.1088/0957-4484/26/1/015602] [PMID: 25490351]
[89]
Shimoni O, Postma A, Yan Y, et al. Macromolecule functionalization of disulfide-bonded polymer hydrogel capsules and cancer cell targeting. ACS Nano 2012; 6(2): 1463-72.
[http://dx.doi.org/10.1021/nn204319b] [PMID: 22260171]
[90]
Stumpel JE, Gil ER, Spoelstra AB, Bastiaansen CWM, Broer DJ, Schenning APHJ. Stimuli‐responsive materials based on interpenetrating polymer liquid crystal hydrogels. Adv Funct Mater 2015; 25(22): 3314-20.
[http://dx.doi.org/10.1002/adfm.201500745]
[91]
INHALERS DP. Committee for Proprietary Medicinal Products. CPMP 1998.
[92]
Sander VA, Sánchez López EF, Mendoza Morales L, Ramos Duarte VA, Corigliano MG, Clemente M. Use of veterinary vaccines for livestock as a strategy to control foodborne parasitic diseases. Front Cell Infect Microbiol 2020; 10: 288.
[http://dx.doi.org/10.3389/fcimb.2020.00288] [PMID: 32670892]
[93]
Rousseau A, La Carbona S, Dumètre A, et al. Assessing viability and infectivity of foodborne and waterborne stages (cysts/oocysts) of Giardia duodenalis, Cryptosporidium spp., and Toxoplasma gondii : a review of methods. Parasite 2018; 25: 14.
[http://dx.doi.org/10.1051/parasite/2018009] [PMID: 29553366]
[94]
Fegan N, Jenson I. The role of meat in foodborne disease: Is there a coming revolution in risk assessment and management? Meat Sci 2018; 144: 22-9.
[http://dx.doi.org/10.1016/j.meatsci.2018.04.018] [PMID: 29716760]
[95]
Flühmann B, Ntai I, Borchard G, Simoens S, Mühlebach S. Nanomedicines: The magic bullets reaching their target? Eur J Pharm Sci 2019; 128: 73-80.
[http://dx.doi.org/10.1016/j.ejps.2018.11.019] [PMID: 30465818]
[96]
Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology 2018; 16(1): 71.
[http://dx.doi.org/10.1186/s12951-018-0392-8] [PMID: 30231877]
[97]
Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science 2020; 367(6485): 1412-3.
[http://dx.doi.org/10.1126/science.367.6485.1412]
[98]
Brandhonneur N, Chevanne F, Vié V, et al. Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur J Pharm Sci 2009; 36(4-5): 474-85.
[http://dx.doi.org/10.1016/j.ejps.2008.11.013] [PMID: 19110055]
[99]
Gomes AJ, Lunardi CN, Caetano FH, Lunardi LO, Machado AEH. Phagocytosis of PLGA microparticles in rat peritoneal exudate cells: A time-dependent study. Microsc Microanal 2006; 12(5): 399-405.
[http://dx.doi.org/10.1017/S1431927606060284] [PMID: 16984666]
[100]
Torchilin V. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006; 58(14): 1532-55.
[http://dx.doi.org/10.1016/j.addr.2006.09.009] [PMID: 17092599]
[101]
Danhier F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release 2016; 244(Pt A): 108-21.
[http://dx.doi.org/10.1016/j.jconrel.2016.11.015] [PMID: 27871992]
[102]
Padera TP, Stoll BR, Tooredman JB, Capen D, Tomaso E, Jain RK. Cancer cells compress intratumour vessels. Nature 2004; 427(6976): 695-5.
[http://dx.doi.org/10.1038/427695a] [PMID: 14973470]
[103]
Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010; 7(11): 653-64.
[http://dx.doi.org/10.1038/nrclinonc.2010.139] [PMID: 20838415]
[104]
Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J Control Release 2012; 161(2): 175-87.
[http://dx.doi.org/10.1016/j.jconrel.2011.09.063] [PMID: 21945285]
[105]
Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv Drug Deliv Rev 2017; 108: 25-38.
[http://dx.doi.org/10.1016/j.addr.2016.04.025] [PMID: 27137110]
[106]
Accomasso L, Cristallini C, Giachino C. Risk assessment and risk minimization in nanomedicine: A need for predictive, alternative, and 3Rs strategies. Front Pharmacol 2018; 9: 228.
[http://dx.doi.org/10.3389/fphar.2018.00228] [PMID: 29662451]
[107]
Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010; 9(8): 615-27.
[http://dx.doi.org/10.1038/nrd2591] [PMID: 20616808]
[108]
Ragelle H, Danhier F, Préat V, Langer R, Anderson DG. Nanoparticle-based drug delivery systems: A commercial and regulatory outlook as the field matures. Expert Opin Drug Deliv 2017; 14(7): 851-64.
[http://dx.doi.org/10.1080/17425247.2016.1244187] [PMID: 27730820]
[109]
Jain MM, Patil S, Pathak AB, et al. The efficacy and safety of paclitaxel injection concentrate for nano-dispersion (PICN) at two different doses versus paclitaxel albumin-stabilized nanoparticle formulation in subjects with metastatic breast cancer (MBC). J Clin Oncol 2014; 32(15_suppl): 1069-9.
[http://dx.doi.org/10.1200/jco.2014.32.15_suppl.1069]
[110]
O’Brien MER, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer. Ann Oncol 2004; 15(3): 440-9.
[http://dx.doi.org/10.1093/annonc/mdh097] [PMID: 14998846]
[111]
Cabral H, Matsumoto Y, Mizuno K, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 2011; 6(12): 815-23.
[http://dx.doi.org/10.1038/nnano.2011.166] [PMID: 22020122]
[112]
Albanese A, Tang PS, Chan WCW. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012; 14(1): 1-16.
[http://dx.doi.org/10.1146/annurev-bioeng-071811-150124] [PMID: 22524388]
[113]
Sun X, Rossin R, Turner JL, et al. An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. Biomacromolecules 2005; 6(5): 2541-54.
[http://dx.doi.org/10.1021/bm050260e] [PMID: 16153091]
[114]
Peer D. Harnessing RNAi nanomedicine for precision therapy. Mol Cell Ther 2014; 2(1): 5.
[http://dx.doi.org/10.1186/2052-8426-2-5] [PMID: 26056574]
[115]
Hrkach J, Von Hoff D, Ali MM, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012; 4(128): 128ra39.
[http://dx.doi.org/10.1126/scitranslmed.3003651] [PMID: 22491949]
[116]
Raza K, Kumar P, Kumar N, Malik R. Pharmacokinetics and biodistribution of the nanoparticles. In: Advances in nanomedicine for the delivery of therapeutic nucleic acids. Woodhead publishing 2017; pp. 165-86.
[http://dx.doi.org/10.1016/B978-0-08-100557-6.00009-2]
[117]
Soo Choi H, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol 2007; 25(10): 1165-70.
[http://dx.doi.org/10.1038/nbt1340] [PMID: 17891134]
[118]
Fang C, Shi B, Pei YY, Hong MH, Wu J, Chen HZ. In vivo tumor targeting of tumor necrosis factor-α-loaded stealth nanoparticles: Effect of MePEG molecular weight and particle size. Eur J Pharm Sci 2006; 27(1): 27-36.
[http://dx.doi.org/10.1016/j.ejps.2005.08.002] [PMID: 16150582]
[119]
Bertrand N, Grenier P, Mahmoudi M, et al. Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics. Nat Commun 2017; 8(1): 777.
[http://dx.doi.org/10.1038/s41467-017-00600-w] [PMID: 28974673]
[120]
Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K. Long-circulating poly(ethylene glycol)–poly(d,l-lactide) block copolymer micelles with modulated surface charge. J Control Release 2001; 77(1-2): 27-38.
[http://dx.doi.org/10.1016/S0168-3659(01)00451-5] [PMID: 11689257]
[121]
van Vlerken LE, Vyas TK, Amiji MM. Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery. Pharm Res 2007; 24(8): 1405-14.
[http://dx.doi.org/10.1007/s11095-007-9284-6] [PMID: 17393074]
[122]
Bertholon I, Vauthier C, Labarre D. Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharm Res 2006; 23(6): 1313-23.
[http://dx.doi.org/10.1007/s11095-006-0069-0] [PMID: 16715369]
[123]
Hu Y, Xie J, Tong YW, Wang CH. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Control Release 2007; 118(1): 7-17.
[http://dx.doi.org/10.1016/j.jconrel.2006.11.028] [PMID: 17241684]
[124]
Musyanovych A, Dausend J, Dass M, Walther P, Mailänder V, Landfester K. Criteria impacting the cellular uptake of nanoparticles: A study emphasizing polymer type and surfactant effects. Acta Biomater 2011; 7(12): 4160-8.
[http://dx.doi.org/10.1016/j.actbio.2011.07.033] [PMID: 21855659]
[125]
Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004; 377(1): 159-69.
[http://dx.doi.org/10.1042/bj20031253] [PMID: 14505488]
[126]
Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine (Lond) 2016; 11(6): 673-92.
[http://dx.doi.org/10.2217/nnm.16.5] [PMID: 27003448]
[127]
Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 2015; 33(9): 941-51.
[http://dx.doi.org/10.1038/nbt.3330] [PMID: 26348965]
[128]
Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 2007; 104(39): 15549-54.
[http://dx.doi.org/10.1073/pnas.0707461104] [PMID: 17875985]
[129]
Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46(12 Pt 1): 6387-92.
[PMID: 2946403]
[130]
Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011; 63(3): 136-51.
[http://dx.doi.org/10.1016/j.addr.2010.04.009] [PMID: 20441782]
[131]
Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer 2008; 8(6): 473-80.
[http://dx.doi.org/10.1038/nrc2394] [PMID: 18469827]
[132]
Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res 2016; 33(10): 2373-87.
[http://dx.doi.org/10.1007/s11095-016-1958-5] [PMID: 27299311]
[133]
Duncan R. Polymer therapeutics: Top 10 selling pharmaceuticals — What next? J Control Release 2014; 190: 371-80.
[http://dx.doi.org/10.1016/j.jconrel.2014.05.001] [PMID: 24818766]
[134]
Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. P&T 2017; 42(12): 742-55.
[PMID: 29234213]
[135]
Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014; 66: 2-25.
[http://dx.doi.org/10.1016/j.addr.2013.11.009] [PMID: 24270007]
[136]
Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008; 60(15): 1615-26.
[http://dx.doi.org/10.1016/j.addr.2008.08.005] [PMID: 18840489]
[137]
Karmali PP, Kotamraju VR, Kastantin M, et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 2009; 5(1): 73-82.
[http://dx.doi.org/10.1016/j.nano.2008.07.007] [PMID: 18829396]
[138]
Marcucci F, Lefoulon F. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discov Today 2004; 9(5): 219-28.
[http://dx.doi.org/10.1016/S1359-6446(03)02988-X] [PMID: 14980540]
[139]
Maruyama K. PEG-Immunoliposome. Biosci Rep 2002; 22(2): 251-66.
[http://dx.doi.org/10.1023/A:1020138622686] [PMID: 12428903]
[140]
Toporkiewicz M, Meissner J, Matusewicz L, Czogalla A, Sikorski AF. Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges. Int J Nanomedicine 2015; 10: 1399-414.
[PMID: 25733832]
[141]
Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2(10): 750-63.
[http://dx.doi.org/10.1038/nrc903] [PMID: 12360278]
[142]
Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013; 73(8): 2412-7.
[http://dx.doi.org/10.1158/0008-5472.CAN-12-4561] [PMID: 23423979]
[143]
Lammers T, Rizzo LY, Storm G, Kiessling F. Personalized Nanomedicine. Clin Cancer Res 2012; 18(18): 4889-94.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-1414] [PMID: 22829203]
[144]
Natfji AA, Ravishankar D, Osborn HMI, Greco F. Parameters affecting the enhanced permeability and retention effect: the need for patient selection. J Pharm Sci 2017; 106(11): 3179-87.
[http://dx.doi.org/10.1016/j.xphs.2017.06.019] [PMID: 28669714]
[145]
Gregoriadis G, Swain CP, Wills EJ, Tavill AS. Drug-carrier potential of liposomes in cancer chemotherapy. Lancet 1974; 303(7870): 1313-6.
[http://dx.doi.org/10.1016/S0140-6736(74)90682-5] [PMID: 4134296]
[146]
Segal AW, Gregoriadis G, Lavender JP, Tarin D, Peters TJ. Tissue and hepatic subcellular distribution of liposomes containing bleomycin after intravenous administration to patients with neoplasms. Clin Sci Mol Med 1976; 51(4): 421-5.
[http://dx.doi.org/10.1042/cs0510421] [PMID: 61088]
[147]
Richardson VJ, Ryman BE, Jewkes RF, et al. Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients. Br J Cancer 1979; 40(1): 35-43.
[http://dx.doi.org/10.1038/bjc.1979.138] [PMID: 475960]
[148]
Perez-Soler R, Lopez-Berestein G, Kasi LP, et al. Distribution of technetium-99m-labeled multilamellar liposomes in patients with Hodgkin’s disease. J Nucl Med 1985; 26(7): 743-9.
[PMID: 3925093]
[149]
Lopez-Berestein G, Kasi L, Rosenblum MG, et al. Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. Cancer Res 1984; 44(1): 375-8.
[PMID: 6317172]
[150]
Turner AF, Presant CA, Proffitt RT, Williams LE, Winsor DW, Werner JL. In-111-labeled liposomes: dosimetry and tumor depiction. Radiology 1988; 166(3): 761-5.
[http://dx.doi.org/10.1148/radiology.166.3.3340774] [PMID: 3340774]
[151]
Perez-Soler R, Lopez-Berestein G, Kasi LP. Cabanillas F, Jahns M, Glenn H, Hersh EM, Haynie T.Distribution of technetium-99mlabeled multilamellar liposomes in patients with Hodgkin's disease. J Nuclear Med 1985; 26(7): 743-9.
[152]
Turner AF, Presant CA. Proffitt RT, Williams LE, Winsor DW, Werner JL. In-111-labeled liposomes: dosimetry and tumor depiction. Radiology 1988; 166(3): 761-5.
[153]
Presant CA, Turner AF. Proffitt RT. Potential for improvement in clinical decision-making: tumor imaging with in-111 labeled liposomes results of a phase ii-iii study. J Liposome Res 1994; 4(2): 985-1008.
[154]
Flacke S, Fischer S, Scott MJ, et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001; 104(11): 1280-5.
[http://dx.doi.org/10.1161/hc3601.094303] [PMID: 11551880]
[155]
Frank JA, Miller BR, Arbab AS, et al. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology 2003; 228(2): 480-7.
[http://dx.doi.org/10.1148/radiol.2281020638] [PMID: 12819345]
[156]
Kraitchman DL, Heldman AW, Atalar E, et al. in vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 2003; 107(18): 2290-3.
[http://dx.doi.org/10.1161/01.CIR.0000070931.62772.4E] [PMID: 12732608]
[157]
Nikalje AP. Nanotechnology and its applications in medicine. Med chem 2015; 5(2): 081-9.
[http://dx.doi.org/10.4172/2161-0444.1000247]
[158]
Thiruppathi R, Mishra S, Ganapathy M, Padmanabhan P, Gulyás B. Nanoparticle functionalization and its potentials for molecular imaging. Adv Sci (Weinh) 2017; 4(3): 1600279.
[http://dx.doi.org/10.1002/advs.201600279] [PMID: 28331783]
[159]
Iacono P, Karabeber H, Kircher MF. A “schizophotonic” all-in-one nanoparticle coating for multiplexed SE(R)RS biomedical imaging. Angew Chem Int Ed 2014; 53(44): 11756-61.
[http://dx.doi.org/10.1002/anie.201403835] [PMID: 25164141]
[160]
Muthukumar T, Chamundeeswari M, Prabhavathi S, Gurunathan B, Chandhuru J, Sastry TP. Carbon nanoparticle from a natural source fabricated for folate receptor targeting, imaging and drug delivery application in A549 lung cancer cells. Eur J Pharm Biopharm 2014; 88(3): 730-6.
[http://dx.doi.org/10.1016/j.ejpb.2014.09.011] [PMID: 25305584]
[161]
Ghaghada KB, Badea CT, Karumbaiah L, et al. Evaluation of tumor microenvironment in an animal model using a nanoparticle contrast agent in computed tomography imaging. Acad Radiol 2011; 18(1): 20-30.
[http://dx.doi.org/10.1016/j.acra.2010.09.003] [PMID: 21145026]
[162]
Hainfeld JF, Smilowitz HM, O’Connor MJ, Dilmanian FA, Slatkin DN. Gold nanoparticle imaging and radiotherapy of brain tumors in mice. Nanomedicine (Lond) 2013; 8(10): 1601-9.
[http://dx.doi.org/10.2217/nnm.12.165] [PMID: 23265347]
[163]
Nahrendorf M, Zhang H, Hembrador S, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008; 117(3): 379-87.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.741181] [PMID: 18158358]
[164]
Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 2012; 64(7): 686-700.
[http://dx.doi.org/10.1016/j.addr.2011.10.007] [PMID: 22100125]
[165]
Pottoo FH, Sharma S, Javed MN, et al. Lipid-based nanoformulations in the treatment of neurological disorders. Drug Metab Rev 2020; 52(1): 185-204.
[http://dx.doi.org/10.1080/03602532.2020.1726942] [PMID: 32116044]
[166]
Ibrahim AM, Chauhan L, Bhardwaj A, et al. Brain-derived neurotropic factor in neurodegenerative disorders. Biomedicines 2022; 10(5): 1143.
[http://dx.doi.org/10.3390/biomedicines10051143] [PMID: 35625880]
[167]
Aslam M, Javed MN, Deeb HH, et al. Lipid carriers mediated targeted delivery of nutraceuticals: Challenges, role of blood brain barrier and promises of nanotechnology based ap-proaches in neuronal disorders. Curr Drug Metab 2020; 21: 21.
[http://dx.doi.org/10.2174/1389200221999200728143511]
[168]
Javed MN, Akhter MH, Taleuzzaman M, Faiyazudin M, Alam MS. Cationic nanoparticles for treatment of neurological diseases. Fundamentals of Bionanomaterials. Elsevier 2022; pp. 273-92.
[http://dx.doi.org/10.1016/B978-0-12-824147-9.00010-8]
[169]
Kumari N, Daram N, Alam MS, Verma AK. Rationalizing the use of polyphenol nano-formulations in the therapy of neurodegenerative diseases. CNS Neurol Disord Drug Targets 2022; 21(10): 966-76.
[170]
Pottoo FH, Tabassum N, Javed MN, et al. The synergistic effect of raloxifene, fluoxetine, and bromocriptine protects against pilocarpine-induced status epilepticus and temporal lobe epilepsy. Mol Neurobiol 2019; 56(2): 1233-47.
[http://dx.doi.org/10.1007/s12035-018-1121-x] [PMID: 29881945]
[171]
Pottoo FH, Javed MN, Barkat MA, et al. Estrogen and serotonin: complexity of interactions and implications for epileptic seizures and epileptogenesis. Curr Neuropharmacol 2019; 17(3): 214-31.
[http://dx.doi.org/10.2174/1570159X16666180628164432] [PMID: 29956631]
[172]
Pottoo FH, Tabassum N, Javed MN, et al. Raloxifene potentiates the effect of fluoxetine against maximal electroshock induced seizures in mice. Eur J Pharm Sci 2020; 146: 105261.
[http://dx.doi.org/10.1016/j.ejps.2020.105261] [PMID: 32061655]
[173]
Chiu SS, Terpstra K, Woodbury-Farina M, et al. Transforming curry extract to liposomal curcumin (LipocurcTM) in Parkinson disease (PD) therapeutics landscape: Emerging role of epigenetics signaling and nanotechnology. EC Neurology 2020; 12(2): 01-12.
[174]
Hu K, Shi Y, Jiang W, Han J, Huang S, Jiang X. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in Parkinson’s disease. Int J Pharm 2011; 415(1-2): 273-83.
[http://dx.doi.org/10.1016/j.ijpharm.2011.05.062] [PMID: 21651967]
[175]
Ko WC, Wang SJ, Hsiao CY, et al. Pharmacological role of functionalized gold nanoparticles in disease applications. Molecules 2022; 27(5): 1551.
[http://dx.doi.org/10.3390/molecules27051551] [PMID: 35268651]
[176]
Liao X, Ge K, Cai Z, et al. Hybridization chain reaction triggered poly adenine to absorb silver nanoparticles for label-free electrochemical detection of Alzheimer’s disease biomarkers amyloid β-peptide oligomers. Anal Chim Acta 2022; 1192: 339391.
[http://dx.doi.org/10.1016/j.aca.2021.339391] [PMID: 35057926]
[177]
Pohanka M. Copper and copper nanoparticles toxicity and their impact on basic functions in the body. Bratisl Med J 2019; 120(6): 397-409.
[http://dx.doi.org/10.4149/BLL_2019_065] [PMID: 31223019]
[178]
Xiang C, Zhang Y, Guo W, Liang XJ. Biomimetic carbon nanotubes for neurological disease therapeutics as inherent medication. Acta Pharm Sin B 2020; 10(2): 239-48.
[http://dx.doi.org/10.1016/j.apsb.2019.11.003] [PMID: 32082970]
[179]
Kreuter J, Ramge P, Petrov V, et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003; 20(3): 409-16.
[http://dx.doi.org/10.1023/A:1022604120952] [PMID: 12669961]
[180]
Costigan S. The toxicology of nanoparticles used in health care products, Medicines and Healthcare Products. Department of Health 2006.
[181]
de Jong . Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine 2008; 133: 133.
[http://dx.doi.org/10.2147/IJN.S596]

Rights & Permissions Print Cite
Article Metrics
143
2
Wayfinder Image
© 2025 Bentham Science Publishers | Privacy Policy